Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safinamide 12-month extension study in Parkinson's disease with motor fluctuations
2006-005861-21Phase 3Completed
- Sponsor
- Newron Pharmaceuticals
- Start
- Jan 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of safinamide in Parkinson's disease (PD) (3 arms), sponsored by Newron Pharmaceuticals. Primary endpoint: Mean change in Dyskinesias Rating Scale during ON time. Started Jan 2007; status: completed.
02
Drugs
safinamide
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2006-005861-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005861-21.